Cabaletta Bio/$CABA
1D1W1MYTD1Y5YMAX
About Cabaletta Bio
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
- Ticker
- $CABA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 155
- Headquarters
- Philadelphia, United States
- Website
- www.cabalettabio.com
Cabaletta Bio Metrics
BasicAdvanced
$490M
-
-$1.54
3.25
-
Price and volume
Market cap
$490M
Beta
3.25
52-week high
$4.23
52-week low
$1.40
Average daily volume
3.6M
Financial strength
Current ratio
5.789
Quick ratio
5.64
Long term debt to equity
2.956
Total debt to equity
12.21
Interest coverage (TTM)
-80.94%
Profitability
EBITDA (TTM)
-184.115
Management effectiveness
Return on assets (TTM)
-48.19%
Return on equity (TTM)
-93.20%
Valuation
Price to book
2.3
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
-2.204
Free cash flow yield (TTM)
-45.37%
Free cash flow per share (TTM)
-1.311
Growth
Earnings per share change (TTM)
-43.35%
3-year earnings per share growth (CAGR)
-3.47%
What the Analysts think about Cabaletta Bio
Analyst ratings (Buy, Hold, Sell) for Cabaletta Bio stock.
Cabaletta Bio Financial Performance
Revenues and expenses
Cabaletta Bio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.